CD56 on immune and tumor cells: what is known and beyond?
Clinical and Experimental Immunology · 2025
DOI: 10.1093/cei/uxaf056 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Clinical and Experimental Immunology, 2025. Verfasst von Yuan Meng und 6 weiteren Autor:innen. Beteiligte Einrichtung: Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China. Hauptthemen laut MEDLINE: CD56 Antigen, Killer Cells, Natural, Neoplasms, Hematologic Neoplasms. Die Arbeit nennt 133 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Science and Technology Project of Sichuan Province of China, Clinical Research Fund, West China Hospital, Sichuan University.
Abstract (Originalsprache)
Recent studies on cancer cells and the immune microenvironment have offered valuable insights into personalized diagnostics, targeted therapies, and individualized prognosis evaluation. A comprehensive understanding of new and existing biomarkers in both healthy and diseased conditions is essential for advancing these goals. CD56, also known as the neural cell adhesion molecule, is a well-established phenotypic marker of natural killer cells. It is also expressed by various immune cells under healthy conditions, such as T cells, dendritic cells, and monocytes. Despite its widespread expression, the functions of CD56 are still poorly understood. In patients with infectious, autoimmune, or malignant diseases, changes in the proportion, phenotype, and function of CD56+ immune cells have been observed. In patients with hematolymphoid disorders, malignant cells may exhibit aberrant CD56 expression, making it a valuable diagnostic and prognostic marker. CD56 also holds potential as a therapeutic target. In this review, we summarize the current understanding of CD56 expression and function across various immune cells in infectious, immune-related, and cancerous conditions. We also explore its diagnostic, prognostic, and therapeutic significance in hematological malignancies. This review aims to present a comprehensive overview of CD56 in hematolymphoid disorders, offering insights into how CD56 and its associated immune cells could inform future immunotherapeutic strategies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Laboratory Medicine, West China Hospital of Sichuan University, Chengdu, China.
ORCID-Profile: Hongyan Liao
Förderung
- Science and Technology Project of Sichuan Province of China
- Clinical Research Fund, West China Hospital, Sichuan University
Zitieren
APA
Meng, Y., Zhang, F., Jin, Y., Wen, Z., Chen, F., Jiang, N., & Liao, H. (2025). CD56 on immune and tumor cells: what is known and beyond?. Clinical and Experimental Immunology. https://doi.org/10.1093/cei/uxaf056
Vancouver
Meng Y, Zhang F, Jin Y, Wen Z, Chen F, Jiang N, et al. CD56 on immune and tumor cells: what is known and beyond?. Clinical and Experimental Immunology. 2025. doi:10.1093/cei/uxaf056
BibTeX
@article{Meng2025,
author = {Meng, Yuan and Zhang, Feng and Jin, Yiying and Wen, Zhihao and Chen, Fengyu and Jiang, Nenggang and Liao, Hongyan},
title = {CD56 on immune and tumor cells: what is known and beyond?},
journal = {Clinical and Experimental Immunology},
year = {2025},
doi = {10.1093/cei/uxaf056}
}
EUVIMED